Literature DB >> 29884905

Response kinetics and factors predicting survival in core-binding factor leukemia.

Prajwal Boddu1, Christopher Gurguis2, David Sanford3, Jorge Cortes1, Mary Akosile1, Farhad Ravandi1, Guillermo Garcia-Manero1, Keyur P Patel4, Tapan Kadia1, Mark Brandt1, Rita Maduike1, Hagop Kantarjian1, Gautam Borthakur5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29884905     DOI： 10.1038/s41375-018-0158-1

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.

Authors:  Nicholas J Short; Chenqi Fu; Donald A Berry; Roland B Walter; Sylvie D Freeman; Christopher S Hourigan; Xuelin Huang; Graciela Nogueras Gonzalez; Hyunsoo Hwang; Xinyue Qi; Hagop Kantarjian; Shouhao Zhou; Farhad Ravandi
Journal:  Leukemia       Date:  2022-10-19       Impact factor: 12.883

3.  [Correlation between serum 25(OH) vitamin D and liver fat content in nonalcoholic fatty liver disease].

Authors:  Likun Fu; Hongmei Cui; Kunling Lu; Chunyan Zou; Guixian Ji; Li Li; Jinglong Li; Lina Sheng; Changshun Xie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-09-30

Review 4.  How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?

Authors:  Nicholas J Short; Farhad Ravandi
Journal:  Haematologica       Date:  2019-07-04       Impact factor: 9.941

5.  Acute myeloid leukemia with variant t(8;10;21).

Authors:  Barbora Bacova; Jiri Sobotka; Petra Kacirkova; Veronika Rivnacova; Ivana Karlova/Zubata; Jan Novak
Journal:  Leuk Res Rep       Date:  2022-09-15

6.  Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.

Authors:  Jayastu Senapati; Mahran Shoukier; Guillermo Garcia-Manero; Xuemei Wang; Keyur Patel; Tapan Kadia; Farhad Ravandi; Naveen Pemmaraju; Maro Ohanian; Naval Daver; Courtney DiNardo; Yesid Alvarado; Jeffrey Aldrich; Gautam Borthakur
Journal:  Am J Hematol       Date:  2022-02-22       Impact factor: 13.265

Review 7.  Core binding factor acute myelogenous leukemia-2021 treatment algorithm.

Authors:  Gautam Borthakur; Hagop Kantarjian
Journal:  Blood Cancer J       Date:  2021-06-16       Impact factor: 11.037
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.